Teva Pharmaceutical Industries announced today that the U.S. Food and Drug Administration (FDA) has approved QNASL Nasal Aerosol, a new ‘dry’ nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years and older. The product is expected to be available by prescription on April 2012 and offers a built-in dose counter. The approval follows a comprehensive clinical development program that assessed the product’s safety and efficacy.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments